Differential desensitization of homozygous haplotypes of the beta2-adrenergic receptor in lymphocytes.

Single-nucleotide polymorphisms of the beta(2)-adrenergic receptor gene and its 5' promoter have been associated with differences in receptor function and desensitization. Linkage disequilibrium may account for inconsistencies in reported effects of isolated polymorphisms. Therefore, we have investigated the three most common homozygous haplotypes of the beta(2)-adrenergic receptor (position 19 [Cys/Arg] of the 5' leader cistron and positions 16 [Arg/Gly] and 27 [Gln/Glu] of the receptor) for putative differences in agonist-induced desensitization. Lymphocytes of well defined nonasthmatic, nonallergic subjects homozygous for the haplotype CysGlyGln, ArgGlyGlu, or CysArgGln were isolated. Desensitization of (-)-isoproterenol-induced cyclic adenosine monophosphate (cAMP) accumulation and beta(2)-adrenergic receptor sequestration and downregulation were measured in relation to beta(2)-adrenergic receptor-mediated inhibition of IFN-gamma and interleukin-5 production. We observed that lymphocytes of individuals bearing the CysGlyGln haplotype were more susceptible to desensitization of the beta-agonist-induced cAMP response than those of individuals with the ArgGlyGlu or CysArgGln haplotype. The haplotype-dependent desensitization of beta-agonist-induced cAMP response was not associated with haplotype-dependent beta(2)-adrenergic receptor sequestration or downregulation. In addition, our data suggest reduced inhibition, in lymphocytes of subjects with the CysGlyGln haplotype, of interleukin-5 production induced by treatment with antibodies to the T-cell receptor-CD3 complex and to costimulatory molecule CD28 (alphaCD3/alphaCD28). This is the first study demonstrating haplotype-related differences in agonist-induced beta(2)-adrenergic receptor desensitization in primary human cells. This haplotype-related desensitization of the beta(2)-adrenergic receptor in lymphocytes might have consequences regarding the regulation of helper T-cell type 2 inflammatory responses.

[1]  E. Salpeter,et al.  Meta-Analysis: Respiratory Tolerance to Regular 2-Agonist Use in Patients with Asthma , 2004, Annals of Internal Medicine.

[2]  L. Plante.  Obstetricians Wanted: No Mothers Need Apply , 2004, Annals of Internal Medicine.

[3]  S. Liggett,et al.  Pharmacology and physiology of human adrenergic receptor polymorphisms. , 2003, Annual review of pharmacology and toxicology.

[4]  D. Postma,et al.  Association of a disintegrin and metalloprotease 33 (ADAM33) gene with asthma in ethnically diverse populations. , 2003, The Journal of allergy and clinical immunology.

[5]  H. Bruck,et al.  Genotype‐dependent time course of lymphocyte β2‐adrenergic receptor down‐regulation , 2003, Clinical pharmacology and therapeutics.

[6]  J. Drazen,et al.  β-Agonists and asthma: too much of a good thing? , 2003 .

[7]  D. Postma,et al.  Sensitivity of IL‐5 production to the cAMP‐dependent pathway in human T cells is reduced by exogenous IL‐2 in a phosphoinositide 3‐kinase‐dependent way , 2003, European journal of immunology.

[8]  D. Postma,et al.  Polarized Th1 and Th2 cells are less responsive to negative feedback by receptors coupled to the AC/cAMP system compared to freshly isolated T cells , 2003, British journal of pharmacology.

[9]  D. Postma,et al.  Cloning, pharmacological characterization, and polymorphism screening of the guinea pig β2-adrenoceptor , 2002 .

[10]  E. Boerwinkle,et al.  β2 adrenergic receptor 5′ haplotypes influence promoter activity , 2002, British journal of pharmacology.

[11]  R. Lefkowitz,et al.  The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. , 2002, Journal of cell science.

[12]  D. Postma,et al.  β2 adrenoceptor promoter polymorphisms: extended haplotypes and functional effects in peripheral blood mononuclear cells , 2002, Thorax.

[13]  R. Kim,et al.  The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. , 2001, The New England journal of medicine.

[14]  R. Pauwels,et al.  Long-acting inhaled β2-agonist therapy in asthma , 2001 .

[15]  Elaine,et al.  Mutational Analysis of ,&Adrenergic Receptor Glycosylation* , 2001 .

[16]  J. Drazen,et al.  Polymorphism of the β2-Adrenergic Receptor Gene and Desensitization in Human Airway Smooth Muscle , 2000 .

[17]  R S Judson,et al.  Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Drazen,et al.  Asthma exacerbations during long term â agonist use : influence of â 2 adrenoceptor polymorphism , 2000 .

[19]  E. Silverman,et al.  The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. , 2000, American journal of respiratory and critical care medicine.

[20]  P. Ghahramani,et al.  Influence of genetic polymorphisms in the β2-adrenoceptor on desensitization in human lung mast cells , 2000 .

[21]  P. Barnes.  Effect of β agonists on inflammatory cells , 1999 .

[22]  I. Hall,et al.  Effects of genetic polymorphism on ex vivo and in vivo function of beta2-adrenoceptors in asthmatic patients. , 1999, Chest.

[23]  S. Liggett,et al.  Polymorphisms of the 5' leader cistron of the human beta2-adrenergic receptor regulate receptor expression. , 1998, The Journal of clinical investigation.

[24]  T D Weir,et al.  beta2-Adrenergic receptor haplotypes in mild, moderate and fatal/near fatal asthma. , 1998, American journal of respiratory and critical care medicine.

[25]  J. Heyder,et al.  Prostanoids mediate IL-1β-induced β-adrenergic hyporesponsiveness in human airway smooth muscle cells. , 1998, American journal of physiology. Lung cellular and molecular physiology.

[26]  I. Hall,et al.  Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma. , 1998, The Journal of allergy and clinical immunology.

[27]  P. Matricardi,et al.  Association of persistent bronchial hyperresponsiveness with beta2-adrenoceptor (ADRB2) haplotypes. A population study. , 1998, American journal of respiratory and critical care medicine.

[28]  D. Cockcroft,et al.  Functional antagonism: tolerance produced by inhaled beta 2 agonists. , 1996, Thorax.

[29]  M. Caron,et al.  Role of β-Arrestin in Mediating Agonist-Promoted G Protein-Coupled Receptor Internalization , 1996, Science.

[30]  M. Caron,et al.  Role of Phosphorylation in Agonist-promoted β2-Adrenergic Receptor Sequestration , 1995, The Journal of Biological Chemistry.

[31]  D. Postma,et al.  Genetic susceptibility to asthma--bronchial hyperresponsiveness coinherited with a major gene for atopy. , 1995, The New England journal of medicine.

[32]  I. Hall,et al.  Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. , 1995, American journal of respiratory cell and molecular biology.

[33]  S. Green,et al.  Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. , 1994, Biochemistry.

[34]  P. Sassone-Corsi,et al.  Transcriptional cross-talk: nuclear factors CREM and CREB bind to AP-1 sites and inhibit activation by Jun. , 1992, The Journal of biological chemistry.

[35]  C. Strader,et al.  Mutational analysis of beta-adrenergic receptor glycosylation. , 1990, The Journal of biological chemistry.

[36]  M. Ward,et al.  Role of glycosylation for beta 2-adrenoceptor function in A431 cells. , 1988, The Journal of biological chemistry.

[37]  K. de Vries,et al.  Regulation of the beta-receptor-adenylate cyclase system in lymphocytes of allergic patients with asthma: possible role for protein kinase C in allergen-induced nonspecific refractoriness of adenylate cyclase. , 1987, The Journal of allergy and clinical immunology.

[38]  H. Sluiter,et al.  Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. , 1985, The Journal of allergy and clinical immunology.

[39]  M. Littner,et al.  Subsensitization of beta-adrenoceptors in airways and lymphocytes of healthy and asthmatic subjects. , 1982, The American review of respiratory disease.

[40]  J. Greenacre,et al.  The lymphocyte beta-adrenoceptor in normal subjects and patients with bronchial asthma: the effect of different forms of treatment on receptor function. , 1976, The Journal of clinical investigation.

[41]  D. Cockcroft,et al.  Functional antagonism : tolerance produced by inhaled 32 agonists , 2022 .